Show description/summary:1) Neurology® Genetics: ExACtly zero or once: A clinically helpful guide to assessing genetic variants in mild epilepsies 2) What's Trending: Orphan drug pricingThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 26, 2017 issue of Neurology. In the first segment, Dr. Jim Kiely talks with Dr. Samuel Berkovic about his Neurology® Genetics paper on assessing genetic variants in mild epilepsies. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Gordon Smith on orphan drug pricing. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Kiely is employed at InTouch Health Physician Services as a teleneurologist, and holds stock with InTouch Health. Dr. Berkovic serves on scientific advisory board for UCB Pharma and Eisai Australia; has served on editorial boards for Brain, Epileptic Disorders, and Lancet Neurology; is an investor listed on a Bionomics Inc patent on diagnostic testing using SCN1A gene (WO2006/133508), and is an investor on a pending patent for a therapeutic compound related to a genetic cause of familial epilepsy with mental retardation in females (WO61/010176); receives research support from UCB, SciGen, and Eisai Australia, the National Health and Medical Research Council of Australia (Program Grant #1091593; 2016-2020), and NINDS (U01 NS077367-01; 2011-2014).Dr. Smith serves on the Celegene data monitoring committee; serves as editor for NeuroLearn; has consulted for Regenesis, Allergan, and Viromed; and receives research support from Impeto Medical, and NIDDK (DK064814), NINDS (U10NS077305 and U10NS086606).Dr. Crowell reports no disclosures.